Anti-dsDNA IgE: a Potential Non-Invasive Test for Prediction of Lupus Nephritis Relapse
RMD Open. 2024 Jun 28;10(2):e004255. doi: 10.1136/rmdopen-2024-004255.
Objectives: The WIN-IgE study aims to assess the value of serum anti-dsDNA IgE autoantibodies as a biomarker for predicting relapse in severe lupus nephritis (LN) to guide the discontinuation or continuation of maintenance immunosuppressive therapy (MIST).
Methods: WIN-IgE is an ancillary study of the WIN-Lupus trial, evaluating the discontinuation of MIST after 2-3 years in class III or IV±V LN with active lesions. Serum samples were collected at randomization for continuation or discontinuation of MIST, and anti-dsDNA antibodies, IgE, and IgG were quantified and compared between patients who experienced LN relapse and those who did not during the 24 months of follow-up.
Results: Initial anti-dsDNA IgE levels were found to be higher in patients who subsequently experienced LN relapse, particularly in the subgroup of patients randomized to discontinue MIST. Anti-dsDNA IgE above 1.9 arbitrary units had a positive predictive value of 0.8 for severe LN relapse.
Conclusions: These results suggest that blood anti-dsDNA IgE could serve as a non-invasive predictive marker of LN relapse.
PMID:38942591 | DOI:10.1136/rmdopen-2024-004255
Clinical Trials and AI-Driven Solutions for Healthcare
Clinical trials play a crucial role in developing safe and effective treatments, and it’s essential to translate their benefits into everyday medical practice. Our AI-driven platform, DocSym, consolidates ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
By leveraging AI, clinics can enhance their workflows, improve patient outcomes, and reduce paper-based routines. Learn more about how we can help at aidevmd.com.
